» Authors » Guan-Jhou Chen

Guan-Jhou Chen

Explore the profile of Guan-Jhou Chen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 41
Citations 246
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Tsai C, Chen G, Tsai C, Liou B, Yang C, Tsai H, et al.
J Microbiol Immunol Infect . 2023 Apr; 56(4):718-728. PMID: 37045634
Background: The short-term impact of sofosbuvir (SOF)-based direct-acting antivirals (DAAs) combined with antiretroviral therapy (ART) on renal function in patients with HIV/HCV-coinfection remains controversial. Methods: This multicenter, retrospective study aimed...
12.
Chen G, Sun H, Lin K, Hsieh S, Chuang Y, Liu W, et al.
Clin Infect Dis . 2023 Apr; 77(4):529-536. PMID: 37036404
Background: For people with human immunodeficiency virus (PWH) who have no serological responses to their primary hepatitis A virus (HAV) vaccination or have seroreversion after successful primary vaccination, the optimal...
13.
Huang M, Chen G, Sun H, Chen Y, Su L, Ho S, et al.
J Microbiol Immunol Infect . 2023 Jan; 56(3):566-574. PMID: 36702644
Background: Understanding the risk behaviors associated with sexually-transmitted hepatitis C virus (HCV) infection among men who have sex with men (MSM) may inform the public health policies and interventions aiming...
14.
Chen G, Palmer J, Bartumeus F, Alba-Casals A
Infect Dis Model . 2022 Nov; 7(4):811-822. PMID: 36411772
Physical distancing and contact tracing are two key components in controlling the COVID-19 epidemics. Understanding their interaction at local level is important for policymakers. We propose a flexible modeling framework...
15.
Chen G, Sun H, Chen L, Hsieh S, Sheng W, Liu W, et al.
Int J Antimicrob Agents . 2022 Jul; 60(3):106631. PMID: 35787920
Real-world experience with low-level viraemia (LLV) and its impact remain less reported among people living with HIV (PLWH) who receive antiretroviral therapy (ART) containing second-generation integrase strand transferase inhibitors, including...
16.
Chen G, Ho S, Su L, Chang S, Hsieh S, Sheng W, et al.
Emerg Microbes Infect . 2022 May; 11(1):1664-1671. PMID: 35608049
To reach the WHO target of hepatitis C virus (HCV) elimination by 2025, Taiwan started to implement free-of-charge direct-acting antiviral (DAA) treatment programme in 2017. Evaluating the progress of HCV...
17.
Chen G, Sun H, Chang S, Su L, Chen Y, Hsieh S, et al.
Emerg Microbes Infect . 2022 Apr; 11(1):1227-1235. PMID: 35412439
Hepatitis C virus (HCV) reinfections after successful treatment with direct-acting antivirals (DAAs) pose a significant challenge to HCV elimination, especially among high-risk people living with HIV (PLWH). In this study,...
18.
Chen G, Sun H, Chang S, Cheng A, Huang Y, Huang S, et al.
Int J Infect Dis . 2021 Feb; 105:147-151. PMID: 33592339
Objectives: The impact of very low-level viremia (VLLV) and low-level viremia (LLV) are rarely investigated among people living with HIV (PLWH) receiving dolutegravir- vs protease inhibitor (PI)-based antiretroviral therapy (ART)....
19.
Chen G, Lee Y, Lee C, Sun H, Cheng C, Tsai H, et al.
J Antimicrob Chemother . 2020 Aug; 75(10):2986-2993. PMID: 32737511
Objectives: Real-world experience regarding the effectiveness of co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (EVG/C/FTC/TAF) as a switch regimen is sparse among people living with HIV (PLWH) harbouring the M184V/I...
20.
Chen G, Lin S, Tsai I, Kuo C, Wang J, Hsieh S
J Formos Med Assoc . 2019 Nov; 119(6):1086-1092. PMID: 31672434
Background: The optimal loading dose of teicoplanin in patients receiving venoarterial extracorporeal membrane oxygenation (VA-ECMO) has never been determined by therapeutic drug monitoring. This study investigated the appropriateness of proposed...